Alexion Pharmaceuticals, Inc.
Head Quarters
100 College Street USWebsite
http://www.alexion.comIndustry
BiotechnologyEmployees
3121Exchange
NASDAQAlexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in New Haven, CT.
Key statistics
| Margins | Stock |
|---|---|
| Revenue per Employee | $0.00 |
| Current Ratio | 3 |
| Gross Margin (%) | 0.82% |
| Net Margin (%) | 0.05% |
| Returns | Stock |
| Sales | $3.20B |
| Sales Growth (% qtr vs. yr ago) | 0.00% |
| Net Income | $308.00M |
| NI Growth (% qtr vs. yr ago) | 0.00% |
| Price/Sales | 48.48 |
| EPS | $2.00 |